Jefferies upgrades Abivax to Buy, raises target to $158
Jefferies upgraded Abivax to Buy with a $158 target, joining BTIG and Wedbush in raising price targets. BTIG set a target of $175 with a Buy rating, while Wedbush maintained a Neutral rating with a $110 target.
*this image is generated using AI for illustrative purposes only.
Jefferies analyst Faisal Khurshid upgraded Abivax (NASDAQ: ABVX) from Hold to Buy and raised the price target to $158 from $108, signaling increased confidence in the biopharmaceutical company's prospects. This adjustment follows a broader trend of positive revisions from Wall Street firms, including BTIG and Wedbush, which have also recalibrated their valuations for the stock.
Rating and Price Action
The revised targets reflect updated valuations following Abivax's continued pipeline development. BTIG analyst Julian Harrison maintained a Buy rating and increased the target to $175 from $150. Separately, Wedbush analyst David Nierengarten maintained a Neutral rating but raised the price target to $110 from $90.
| Firm | Analyst | Rating | Previous Target | New Target |
|---|---|---|---|---|
| Jefferies | Faisal Khurshid | Buy | $108 | $158 |
| BTIG | Julian Harrison | Buy | $150 | $175 |
| Wedbush | David Nierengarten | Neutral | $90 | $110 |
The Buy ratings from Jefferies and BTIG suggest an expectation for the stock to outperform the market, whereas Wedbush's Neutral rating indicates a performance expected to align with the broader market.
What specific pipeline developments are driving the increased confidence among analysts?
How might the divergent ratings between Jefferies/BTIG and Wedbush influence investor sentiment?
What are the potential market reactions if Abivax meets or exceeds these revised price targets?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
